FN2 Earnings Intelligence

Neurocrine Biosciences (NBIX) earnings history

Neurocrine Biosciences, Inc. (NBIX) quarterly earnings scorecards, market reactions, transcript intelligence, and historical context.

NBIX FY2026 Q3 · Calendar Q4 2026

Neurocrine Biosciences, Inc.

The quarter supports a growth thesis built on momentum across INGREZZA, CRENESITY and VYKAT XR, with a higher INGREZZA outlook and multiple pipeline programs advancing. The thesis remains exposed to pricing pressure, VYKAT XR safety and persistence questions, and the uncertainty inherent in clinical development.

EPS surprise+72.3%
Market move-0.5%

Get the NBIX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.